Verastem, Inc. (VSTM) is a publicly traded Healthcare sector company. As of May 21, 2026, VSTM trades at $4.23 with a market cap of $374.34M and a P/E ratio of -1.73. VSTM moved -0.72% today. Year to date, VSTM is -39.88%; over the trailing twelve months it is -48.57%. Its 52-week range spans $2.54 to $11.25. Analyst consensus is strong buy with an average price target of $16.00. Rallies surfaces VSTM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Verastem Updates Q1 Results, Highlights Phase II/III Oncology Pipeline Progress: Verastem Therapeutics published its first-quarter earnings snapshot on May 7, outlining operating highlights and pipeline advancements without disclosing revenue or EPS figures. The update emphasized continued investment in small-molecule oncology candidates, including Phase II and III trials for defactinib and VS-6766.
| Metric | Value |
|---|---|
| Price | $4.23 |
| Market Cap | $374.34M |
| P/E Ratio | -1.73 |
| EPS | $-2.40 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.25 |
| 52-Week Low | $2.54 |
| Volume | 2.58K |
| Avg Volume | 0 |
| Revenue (TTM) | $49.59M |
| Net Income | $-193.96M |
| Gross Margin | 0.00% |
7 analysts cover VSTM: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $16.00.